Literature DB >> 10076907

The SCID/Beige mouse as a model to investigate protection against Yersinia pestis.

M Green1, D Rogers, P Russell, A J Stagg, D L Bell, S M Eley, R W Titball, E D Williamson.   

Abstract

In this study, we have shown that severe combined immunodeficient/beige mice reconstituted with hyperimmune Balb/c lymphocytes can be used as a model to demonstrate adoptive and passive protection against plague infection. Reconstitution of severe combined immunodeficient/beige mice was successful in nine out of ten mice as demonstrated by spleen colonisation and sustained circulating immunoglobulin titres. Furthermore, an increase in antibody titre was evident after a booster immunisation of reconstituted mice. Presence of circulating antibody correlated with protection against a systemic plague challenge and indicated that in reconstituted mice adoptive transfer of a functional immune system had occurred. The severe combined immunodeficient/beige mouse was also used to demonstrate passive protection against inhaled and systemic plague infection. The reconstituted severe combined immunodeficient/beige mouse model demonstrating protective immunity against plague will be further developed to identify the immune cell subsets responsible for this protection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076907     DOI: 10.1111/j.1574-695X.1999.tb01229.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  28 in total

1.  Fibronectin coating of collagen modules increases in vivo HUVEC survival and vessel formation in SCID mice.

Authors:  T P Cooper; M V Sefton
Journal:  Acta Biomater       Date:  2010-11-06       Impact factor: 8.947

Review 2.  Prioritizing therapeutic targets using patient-derived xenograft models.

Authors:  K A Lodhia; A M Hadley; P Haluska; C L Scott
Journal:  Biochim Biophys Acta       Date:  2015-03-14

3.  An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model.

Authors:  E D Williamson; P M Vesey; K J Gillhespy; S M Eley; M Green; R W Titball
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.

Authors:  Anthony J Hickey; Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Debra K Duso; Michael Tighe; Michelle A Parent; Stephen T Smiley
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

5.  Human immune response to a plague vaccine comprising recombinant F1 and V antigens.

Authors:  E D Williamson; H C Flick-Smith; C Lebutt; C A Rowland; S M Jones; E L Waters; R J Gwyther; J Miller; P J Packer; M Irving
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Authors:  Shixia Wang; Jon D Goguen; Fusheng Li; Shan Lu
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

7.  Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.

Authors:  William Bowen; Lalit Batra; Amanda R Pulsifer; Esma S Yolcu; Matthew B Lawrenz; Haval Shirwan
Journal:  Vaccine       Date:  2019-08-12       Impact factor: 3.641

8.  Yersinia pestis V protein epitopes recognized by CD4 T cells.

Authors:  Michelle A Parent; Kiera N Berggren; Isis K Mullarky; Frank M Szaba; Lawrence W Kummer; Jeffrey J Adamovicz; Stephen T Smiley
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

Review 9.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

10.  D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.

Authors:  Frank M Szaba; Lawrence W Kummer; Lindsey B Wilhelm; Jr-Shiuan Lin; Michelle A Parent; Sara W Montminy-Paquette; Egil Lien; Lawrence L Johnson; Stephen T Smiley
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.